Advances in the Proteomic Discovery of Novel Therapeutic Targets in Cancer

Funding Source

National Institutes of Health/National Institute on Minority and Health Disparities, Louisiana Cancer Research Consortium, Department of Agriculture, Office of Naval Research

Grant Number

8G12MD007590 (JZ), 3G12MD007595 (GW), 58-6435-7-019 (GW), N00014-99-1-0763 (GW)


Department of Chemistry

Document Type


Publication Date



Proteomic approaches are continuing to make headways in cancer research by helping to elucidate complex signaling networks that underlie tumorigenesis and disease progression. This review describes recent advances made in the proteomic discovery of drug targets for therapeutic development. A variety of technical and methodological advances are overviewed with a critical assessment of challenges and potentials. A number of potential drug targets, such as baculoviral inhibitor of apoptosis protein repeat-containing protein 6, macrophage inhibitory cytokine 1, phosphoglycerate mutase 1, prohibitin 1, fascin, and pyruvate kinase isozyme 2 were identified in the proteomic analysis of drug-resistant cancer cells, drug action, and differential disease state tissues. Future directions for proteomics-based target identification and validation to be more translation efficient are also discussed.


DOI: 10.2147/DDDT.S52216

PubMed ID: 24187485


This work was funded in part by the National Institutes of Health/National Institute on Minority and Health Disparities grant number 8G12MD007590 (JZ) and 3G12MD007595 (GW), the Louisiana Cancer Research Consortium (GW), the Department of Agriculture Grant 58-6435-7-019 (GW), and the Office of Naval Research Grant N00014-99-1-0763 (GW).